Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis

Journal of Infection

Volumn 64, Issue 2, 2012, Pages 204-211

  Pineda, Juan A ^a   Neukam, Karin ^a   Mallolas, Josep ^b   López Cortés, Luis F ^c,d   Cartón, José A ^e   Domingo, Pere ^f   Moreno, Santiago ^g   Iribarren, José A ^h   Clotet, Bonaventura ⁱ   Crespo, Manuel ^j   de Los Santos, Ignacio ^k   Ortega, Enrique ^l   Knobel, Hernando ^m   Jiménez Expósito, María J ⁿ   Macías, Juan ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d Instituto de Biomedicina de Sevilla   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^m HOSPITAL DEL MAR   (Spain)

ⁿ Bristol Meyers Squibb   (Spain)

more..

Author keywords

Cirrhosis; Efavirenz; Hepatitis C; HIV; Liver fibrosis; Transaminase elevations

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 84855875733     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.10.016     Document Type: Article

References (31)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents December 1, 2009, Department of Health and Human Services, Available from:, [Table5a, accessed 2 June 2010]1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. BG Gazzard on behalf of the BHIVA Treatment Guidelines Writing Group British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine 2008, 9:563-608.
3. Hammer S.M., Eron J.J., Reiss P., Schooley R.S., Thompsom M.A., Cahn P., et al. Antiretroviral treatment of adult HIV Infection. 2008 Recommendations of the International AIDS Society - USA Panel. JAMA 2008, 300:555-570.
4. Clumeck N, Dedes N, Pozniak A, Raffi F, The ECAS Executive Committee. Clinical management and treatment of HIV-infected adults in Europe. Available from: [accessed 2 June 2010]. http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf.
5. Soriano V., Vispo E., Labarga P., Medrano J., Barreiro P. Viral hepatitis and HIV-coinfection. Antivir Res 2010, 85:303-315.
6. Pineda J.A., González J., Ortega E., Tural C., Macías J., Griffa L., et al. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2010, 17:714-719.
7. Bristol-Myers S. Sustiva® (efavirenz): full prescribing information. Available from: [accessed 2 June 2010]. http://packageinserts.bms.com/pi/pi_sustiva.pdf.
8. Meynard J.L., Lacombe K., Poirier J.M., Legrand J., Morand-Joubert L., Girard P.M. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. J Antimicrob Chemother 2009, 63:579-584.
9. Barreiro P., Rodríguez-Novoa S., Labarga P., Ruiz A., Jiménez-Nácher I., Martín-Carbonero L., et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007, 195:973-979.
10. Aranzabal L., Casado J.L., Moya J., Quereda C., Diz S., Moreno A., et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005, 40:588-593.
11. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991, 13:372-374.
12. Pineda J.A., Santos J., Rivero A., Abdel-Kader L., Palacios R., Camacho A., et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008, 61:925-932.
13. Macías J., Orihuela F., Rivero A., Viciana P., Marquez M., Portilla J., et al. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. J Antimicrob Chemother 2009, 63:178-183.
14. Vergara S., Macías J., Rivero A., Gutiérrez-Valencia A., González-Serrano M., Merino D., et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C coinfection. Clin Infect Dis 2007, 45:969-974.
15. Vispo E., Barreiro P., del Valle J., de Ledinghen V., Quereda C., Moreno A., et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther 2009, 14:187-193.
16. Sterling R.K., Lissen E., Clumeck N., Sola R., Correa M.C., Montaner J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
17. Tural C., Tor J., Sanvisens A., Pérez-Alvárez N., Martínez E., Ojanguren I., et al. Accuracy of simple biochmical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009, 7:339-345.
18. Pineda J.A., Aguilar-Guisado M., Rivero A., Girón-González J.A., Ruiz-Morales J., Merino D., et al. Natural history of compensated hepatitis C virus-related cirrhosis in human immunodeficiency virus-infected patients. Clin Infect Dis 2009, 49:1274-1282.
19. Merchante N., Girón-González J.A., González-Serrano M., Torre-Cisneros J., García-García J.A., Arizcorreta A., et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006, 20:49-57.
20. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Sueliman J.M., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004, 292:191-201.
21. DeJesus E., Herrera G., Teofilo E., Gerstoft J., Buendia C.B., Brand J., et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. Clin Infect Dis 2004, 39:1038-1046.
22. Sulkowski M.S., Thomas D.L., Mehta S.H., Chaisson R.E., Moore R.E. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189.
23. Martin-Carbonero L., Nuñez M., González-Lahoz J., Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003, 4:115-120.
24. Bonacini M. Liver injury during highly active antiretroviral therapy: the effects of hepatitis C coinfection. Clin Infect Dis 2004, 38(2):S104-S108.
25. Grant P.M., Komarow L., Andersen J., Sereti I., Pahwa S., Lederman M.M., et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010, 5:e11416.
26. Stern J.O., Robinson P.A., Love J., Lanes S., Imperiale M.S., Mayers D.L. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003, 34(1):S21-S33.
27. Rivero A., Mira J.A., Pineda J.A. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007, 59:342-346.
28. Kappelhoff B.S., Van Leth F., Robinson P.A., McGregor T.R., Baraldi E., Montella F., et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 2005, 10:489-498.
29. van Luin M., Bannister W.P., Mocroft A., Reiss P., Di Perri G., Peytavin G., et al. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther 2009, 14:75-83.
30. McGovern B.H., Golan Y., Lopez M., Pratt D., Lawton A., Moore G., et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007, 44:431-437.
31. Arribas J.R., Horban A., Gerstoft J., Fätkenheuer G., Nelson M., Clumeck N., et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010, 24:223-230.